Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Sensus Healthcare, Inc.

Ticker
SRTS
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent earnings call transcripts and highlights from Q1 to Q3 2026 provide insights into operational performance and strategic initiatives.

Recent developments:
  • Sensus Healthcare reported Q3 2026 earnings with revenue of $5.995 million and a net loss of $1.493 million, reflecting ongoing investment in growth and operations [N1].
  • The company launched Sensus Healthcare Financial Services in February 2026 to facilitate customer acquisition through financing options [N2].
  • Sensus introduced Sensus Link, a cloud-based software solution, in early 2026 to enhance workflow and treatment documentation for its installed base [N3].
  • Q2 2026 earnings call highlighted continued focus on expanding market penetration and operational healthcare services [N2][N3].
  • Q1 2026 earnings call emphasized the company's multi-tier sales strategy targeting dermatology and radiation oncology markets [N4][N5].
Overview

Sensus Healthcare, Inc. develops and markets medical devices based on proprietary low-energy X-ray superficial radiation therapy (SRT) technology for treating non-melanoma skin cancer and keloid scars. Its product portfolio includes the SRT-100, SRT-100+, and SRT-100 Vision systems, which offer non-invasive treatment alternatives to surgery and traditional radiation therapy. The company also provides operational healthcare services, consumables, and financing programs to support customer acquisition and retention. Sensus operates primarily in the U.S. dermatology and radiation oncology markets, with international presence in 21 countries. Manufacturing is outsourced to U.S.-based third parties, and the company holds multiple patents protecting its technology. Sensus complies with FDA Class II medical device regulations and maintains a multi-tier sales strategy involving direct sales and distributors.

Executive summary

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive superficial radiation therapy (SRT) for non-melanoma skin cancer and keloid scar prevention. The company markets its proprietary SRT-100 product line and offers a recurring revenue Fair Deal Agreement service model. As of late 2025, it had installed 955 units globally. Recent financial data as of September 30, 2026, shows $12.92 million in cash, $34.58 million in current assets, and a current ratio of 6.77. The company reported $5.995 million in revenue and a net loss of $1.493 million for Q3 2026. Sensus also launched financing and cloud-based software solutions in early 2026 to support sales and enhance product capabilities. The company operates under FDA Class II medical device regulations and maintains multiple patents and trademarks. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for SRTS

Bull case model:

Sensus Healthcare's proprietary SRT technology offers a non-invasive, effective alternative to surgery and traditional radiation therapy for non-melanoma skin cancer and keloids, addressing a significant patient population. The company's recurring revenue Fair Deal Agreement and financing programs reduce barriers to adoption and support scalable growth. The launch of Sensus Link cloud-based software enhances product capabilities and customer value. The company's multi-tier sales strategy targets key markets with direct and distributor channels. Strong patent protection and FDA clearances support competitive positioning. Operational healthcare services and consumables provide additional revenue streams and customer engagement.

Bear case model:

Sensus Healthcare operates in a highly competitive medical device market with rapid technological changes and alternative treatment methods. The company faces risks related to regulatory compliance, including FDA requirements and potential changes in healthcare laws. Dependence on third-party manufacturers and a single preferred supplier for major components could pose supply chain risks. The company has reported net losses and negative earnings per share, indicating ongoing profitability challenges. Market acceptance depends on physician and patient adoption, reimbursement qualification, and effective marketing. Intellectual property rights may be challenged or circumvented, potentially eroding competitive advantages.

Moat:

Sensus Healthcare's moat is based on its proprietary SRT technology, supported by multiple patents and FDA clearances for non-melanoma skin cancer and keloid treatment. The company's integrated product and service offerings, including the Fair Deal Agreement recurring revenue model and financing programs, create customer lock-in and recurring revenue streams. Its cloud-based Sensus Link software enhances device functionality and workflow, differentiating its installed base. The company's focus on dermatology and radiation oncology markets, combined with operational healthcare services and consumables, supports a comprehensive ecosystem. However, the medical device industry is competitive and subject to rapid technological change, requiring ongoing innovation and regulatory compliance.

Risks overview
Risks summary
Regulatory compliance and competitive pressures represent significant risks to Sensus Healthcare's business model and market position.
Risks details:

• Regulatory Compliance Risk: Sensus's products are subject to extensive FDA and other regulatory requirements. Changes in regulations or failure to comply could impact product availability and increase costs.
• Competitive Risk: The medical device industry is highly competitive with rapid technological change. Competitors may introduce superior or more cost-effective treatments.
• Supply Chain Risk: The company relies on third-party manufacturers and a single preferred supplier for key components, which could lead to disruptions or increased costs.
• Profitability Risk: Sensus has reported net losses and negative EPS, indicating challenges in achieving sustained profitability.
• Intellectual Property Risk: Patents and trademarks may not provide meaningful protection if challenged, invalidated, or circumvented by competitors.

FINAL FORECAST FOR SRTS

Final take one line
Sensus Healthcare demonstrates very high visibility through detailed SEC disclosures and recent earnings calls, showing a clear business model centered on proprietary SRT technology and diversified revenue streams.
Final take 12 to 24 month view

Business trends: Continued focus on expanding adoption of SRT technology in dermatology and radiation oncology markets, supported by financing and cloud-based software solutions.
Execution milestones: Implementation of Fair Deal Agreement recurring revenue model, launch of Sensus Link software, and expansion of operational healthcare services.
Key risks: Regulatory compliance challenges, competitive pressures, supply chain dependencies, profitability concerns, and intellectual property protection risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Sensus Healthcare, Inc. is a medical device company focused on non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention using proprietary low-energy X-ray superficial radiation therapy (SRT) technology.
  • The company’s core products include the SRT-100, SRT-100+, and SRT-100 Vision devices, which provide treatment options for NMSC and keloids with advantages such as non-invasiveness, no need for anesthetics, and improved cosmetic outcomes.
  • As of December 31, 2025, Sensus had installed 955 units in 21 countries, primarily in the U.S.
  • The company operates a recurring revenue program called the Fair Deal Agreement, providing customers with a revenue-share turnkey solution including equipment, technologist support, and oversight.
  • In February 2026, Sensus launched a financing program to support acquisition of its systems through third-party banks, offering purchase and leasing options.
  • Also in February 2026, the company launched Sensus Link, a cloud-based software and connectivity solution to enhance workflow and treatment documentation for installed SRT-100 systems.
  • Sensus offers a Sentinel service program covering parts, labor, and preventive maintenance for its systems.
  • The company sells consumables such as disposable lead shielding, radiation safety items, ultrasound probe film, and applicator tips.
  • Sensus provides operational healthcare services including radiation oncology and physicist oversight and on-site device operation by radiotherapy technologists.
  • Manufacturing is outsourced to third parties in the U.S., with agreements in place to ensure quality and capacity to meet demand.
  • The company holds eight issued U.S. and global patents related to its technology, with patent expirations ranging from 2033 to 2039, and owns eight U.S. trademark registrations.
  • Sensus’s products are FDA Class II medical devices requiring 510(k) clearance, subject to federal and state regulatory requirements.
  • The company’s sales focus is on private dermatology practices and radiation oncologists, using a multi-tier sales strategy including direct sales in the U.S. and international distributors.
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $12.92 million, current assets of $34.58 million, current liabilities of $5.11 million, a current ratio of 6.77, and a cash ratio of 2.53.
  • Revenue for the quarter ending September 30, 2026, was $5.995 million with a net loss of $1.493 million and basic and diluted EPS of -$0.09.
  • The company’s business model includes product sales, recurring revenue from service agreements, financing programs, and operational healthcare services.
  • Sensus faces competition from other treatment methods for NMSC and keloids, with competitive factors including clinical outcomes, ease of use, price, reimbursement, and marketing effectiveness.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
  • N1
  • N2
  • N3
  • N4
  • N5
  • N6
  • N7
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-04 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Sensus Healthcare (SRTS) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/sensus-healthcare-srts-q3-2026-earnings-call-transcript
  • N2 | 2026-08-20 | www.nasdaq.com | Sensus (SRTS) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/sensus-srts-q2-2026-earnings-call-transcript
  • N3 | 2026-08-14 | www.nasdaq.com | Sensus Healthcare Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/sensus-healthcare-q2-earnings-call-highlights
  • N4 | 2026-05-09 | www.nasdaq.com | Sensus Healthcare Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/sensus-healthcare-q1-earnings-call-highlights
  • N5 | 2026-05-07 | www.nasdaq.com | Sensus (SRTS) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/sensus-srts-q1-2026-earnings-transcript
  • N6 | 2026-02-12 | www.nasdaq.com | Sensus Healthcare SRTS Q4 2025 Earnings Transcript | https://www.nasdaq.com/articles/sensus-healthcare-srts-q4-2025-earnings-transcript
  • N7 | 2025-11-06 | www.nasdaq.com | Sensus SRTS Q3 2025 Earnings Call Transcript | https://www.nasdaq.com/articles/sensus-srts-q3-2025-earnings-call-transcript
  • N8 | 2025-11-06 | www.nasdaq.com | Sensus Healthcare, Inc. (SRTS) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/sensus-healthcare-inc-srts-reports-q3-loss-tops-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine